The identification of the TMPRSS2:ERG fusion in prostate cancer suggests that distinct molecular subtypes may define risk for disease progression. In surgical series, TMPRSS2:ERG fusion was identified in 50\% of the tumors. Here, we report on a population-based cohort of men with localized prostate cancers followed by expectant (watchful waiting) therapy with 15\% (17/111) TMPRSS2:ERG fusion. We identified a statistically significant association between TMPRSS2:ERG fusion and prostate cancer specific death (cumulative incidence ratio=2.7, P<0.01, 95\% confidence interval=1.3-5.8). Quantitative reverse-transcription-polymerase chain reaction demonstrated high ets-related [corrected] gene (ERG) expression to be associated with TMPRSS2:ERG fusion (P<0.005). These data suggest that TMPRSS2:ERG fusion prostate cancers may have a more aggressive phenotype, possibly mediated through increased ERG expression.
Scheda prodotto non validato
I dati visualizzati non sono stati ancora sottoposti a validazione formale da parte dello Staff di IRIS, ma sono stati ugualmente trasmessi al Sito Docente Cineca (Loginmiur).
Titolo: | TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. |
Autori: | Demichelis, Francesca; K., Fall; S., Perner; O., Andrén; F., Schmidt; S. R., Setlur; Y., Hoshida; J., Mosquera; Y., Pawitan; C., Lee; H., Adami; L. A., Mucci; P. W., Kantoff; S., Andersson; A. M., Chinnaiyan; J., Johansson; M. A., Rubin |
Autori Unitn: | |
Titolo del periodico: | ONCOGENE |
Anno di pubblicazione: | 2007 |
Codice identificativo Scopus: | 2-s2.0-34547946754 |
Codice identificativo Pubmed: | 17237811 |
Codice identificativo ISI: | WOS:000248801900017 |
Digital Object Identifier (DOI): | http://dx.doi.org/10.1038/sj.onc.1210237 |
Handle: | http://hdl.handle.net/11572/88989 |
Appare nelle tipologie: | 03.1 Articolo su rivista (Journal article) |